Late urinary toxicity modeling after stereotactic body radiotherapy (SBRT) in the definitive treatment of localized prostate cancer

References

• Dasu A, Toma-Dasu I. Prostate alpha/beta revisited – an analysis of clinical results from 14 168 patients. Acta Oncol 2012;51:963–74.
   PubMed Web of Science ®Google Scholar
• Miralbell R, Roberts SA, Zubizarreta E, Hendry JH. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: Alpha/beta = 1.4 (0.9–2.2) Gy. Int J Radiat Oncol Biol Phys 2012;82:e17–24.
   PubMedGoogle Scholar
• Proust-Lima C, Taylor JM, Secher S, Sandler H, Kestin L, Pickles T, et al. Confirmation of a low alpha/beta ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics. Int J Radiat Oncol Biol Phys. 2011;79:195–201.
   PubMed Web of Science ®Google Scholar
• American Society for Radiation Oncology (ASTRO) Model Policy on Steretoactic Body Radiotherapy 2013. Available from: http://www.astro.org/uploadedFiles/Main_Site/Practice_Management/Reimbursement/2013HPcoding%20guidelines_SBRT_Final.pdf. Accessed 17th, April 2013.
   Google Scholar
• King CR, Freeman D, Kaplan I, Fuller D, Bolzicco G, Collins S, et al. Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol 2013;109:217–21.
   PubMed Web of Science ®Google Scholar
• Chen LN, Suy S, Uhm S, Oermann EK, Ju AW, Chen V, et al. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: The Georgetown University experience. Radiat Oncol 2013;8:58.
   PubMed Web of Science ®Google Scholar
• Freeman DE, King CR. Stereotactic body radiotherapy for low-risk prostate cancer: Five-year outcomes. Radiat Oncol 2011;6:3.
   PubMed Web of Science ®Google Scholar
• Katz AJ, Santoro M, Diblasio F, Ashley R. Stereotactic body radiotherapy for localized prostate cancer: Disease control and quality of life at 6 years. Radiat Oncol 2013;8:118.
   PubMed Web of Science ®Google Scholar
• King CR, Brooks JD, Gill H, Presti JC, Jr. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys Feb 2012;82:877–82.
   PubMed Web of Science ®Google Scholar
• McBride SM, Wong DS, Dombrowski JJ, Harkins B, Tapella P, Hanscom HN, et al. Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: Preliminary results of a multi-institutional phase 1 feasibility trial. Cancer 2012;118(15):3681–90.
   PubMed Web of Science ®Google Scholar
• Woo JA, Chen LN, Bhagat A, Oermann EK, Kim JS, Moures R, et al. Clinical characteristics and management of late urinary symptom flare following stereotactic body radiation therapy for prostate cancer. Front Oncol 2014;4:122.
   PubMedGoogle Scholar
• Cesaretti JA, Stone NN, Stock RG. Urinary symptom flare following I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys 2003;56:1085–92.
   PubMed Web of Science ®Google Scholar
• Keyes M, Miller S, Moravan V, Pickles T, Liu M, Spadinger I, et al. Urinary symptom flare in 712 125I prostate brachytherapy patients: Long-term follow-up. Int J Radiat Oncol Biol Phys. 2009;75:649–55.
   PubMed Web of Science ®Google Scholar
• Lehrer S, Cesaretti J, Stone NN, Stock RG. Urinary symptom flare after brachytherapy for prostate cancer is associated with erectile dysfunction and more urinary symptoms before implantation. Br J Urol Int 2006;98:979–81.
   Google Scholar
• Crook J, Fleshner N, Roberts C, Pond G. Long-term urinary sequelae following 125iodine prostate brachytherapy. J Urol 2008;179:141–5; discussion 6.
   PubMed Web of Science ®Google Scholar
• Martinez AA, Pataki I, Edmundson G, Sebastian E, Brabbins D, Gustafson G. Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: A feasibility report. Int J Radiat Oncol Biol Phys 2001;49:61–9.
   PubMed Web of Science ®Google Scholar
• Michalski JM, Gay H, Jackson A, Tucker SL, Deasy JO. Radiation dose-volume effects in radiation-induced rectal injury. Int J Radiat Oncol Biol Phys 2010;76(3 Suppl):S123–9.
   PubMed Web of Science ®Google Scholar
• Descovich M, Carrara M, Morlino S, Pinnaduwage DS, Saltiel D, Pouliot J, et al. Improving plan quality and consistency by standardization of dose constraints in prostate cancer patients treated with CyberKnife. J Appl Clin Med Phys 2013;14:162–72.
   PubMed Web of Science ®Google Scholar
• Wu B, Pang D, Lei S, Gatti J, Tong M, McNutt T, et al. Improved robotic stereotactic body radiation therapy plan quality and planning efficacy for organ-confined prostate cancer utilizing overlap-volume histogram-driven planning methodology. Radiother Oncol 2014;112:221–6.
   PubMed Web of Science ®Google Scholar
• Elias E, Helou J, Zhang L, Cheung P, Deabreu A, D’Alimonte L, et al. Dosimetric and patient correlates of quality of life after prostate stereotactic ablative radiotherapy. Radiother Oncol 2014;112:83–8.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987;40:373–83.
   PubMedGoogle Scholar
• Yu JB, Cramer LD, Herrin J, Soulos PR, Potosky AL, Gross CP. Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: Comparison of toxicity. J Clin Oncol 2014;32: 1195–201.
   PubMed Web of Science ®Google Scholar
• Cheung MR, Tucker SL, Dong L, de Crevoisier R, Lee AK, Frank S, et al. Investigation of bladder dose and volume factors influencing late urinary toxicity after external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2007;67:1059–65.
   PubMed Web of Science ®Google Scholar
• Ghadjar P, Zelefsky MJ, Spratt DE, Munck af Rosenschold P, Oh JH, Hunt M, et al. Impact of dose to the bladder trigone on long-term urinary function after high-dose intensity modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2014;88:339–44.
   PubMed Web of Science ®Google Scholar